{
    "nct_id": "NCT05497453",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2022-08-11",
    "study_start_date": "2022-08-19",
    "study_completion_date": "2024-11-21",
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: Tyrosine kinase inhibitor Two"
            },
            {
                "drug_name": "Drug: Checkpoint Inhibitor, Immune"
            },
            {
                "drug_name": "Drug: Tyrosine kinase inhibitor One"
            },
            {
                "drug_name": "Drug: OTX-2002"
            }
        ]
    },
    "long_title": "Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of OTX-2002 As a Single Agent and in Combination with Standard of Care in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene",
    "last_updated": "2025-02-03",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE1",
    "principal_investigator": "NA, Thomas Yau",
    "principal_investigator_institution": "Omega Therapeutics, HKU",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [
        "OTX-2002-101"
    ],
    "protocol_no": "",
    "protocol_target_accrual": 24,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Key inclusion",
        "* Participants with metastatic, advanced (non-resectable), or recurrent solid tumor who progressed on, relapsed after, are refractory to, or intolerant of standard of care (only applicable to Part 1 escalation)",
        "* Participants with BCLC Stage B (intermediate stage) or C (advanced stage), Child-Pugh A hepatocellular carcinoma who is not amenable to locoregional therapy, refractory to locoregional therapy or not amenable to curative treatment approach",
        "* Adult participants age \u2265 18 years at the time of signing informed consent",
        "* Participant must have progressed on, have relapsed after, be refractory to, or be intolerant of at least 1 prior systemic therapy, and without available subsequent standard of care",
        "* Participants with chronic hepatitis B must have received antiviral therapy for hepatitis B virus (HBV) for at least 12 weeks and HBV viral load must be \\< 500 IU/mL prior to first dose of study drug.",
        "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
        "Key exclusion",
        "* Mixed histology cholangiocarcinoma and HCC, or fibrolamellar variant HCC",
        "* Hepatocellular carcinoma with \u2265 50% liver occupation",
        "* Clear invasion into the bile duct",
        "* Portal vein invasion with Vp4",
        "* Active/untreated CNS metastases or carcinomatous meningitis",
        "* History of ascites requiring paracentesis within the past 3 months",
        "* Esophageal or gastric variceal bleeding in the past 3 months",
        "* History of hepatic encephalopathy in the past 3 months."
    ],
    "short_title": "A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Omega Therapeutics",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "This is a Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma (HCC) and other solid tumor types known for association with the MYC oncogene.\n\nThe study consists of Part 1 (OTX-2002 monotherapy) and Part 2 (OTX-2002 combined with standard of care in hepatocellular carcinoma). Part 1 consists of escalation and expansion, and Part 2 consists of safety run-in and expansion. The objective of Part 1 escalation and Part 2 safety run-in will be safety and tolerability, while anti-tumor activity will be evaluated as the primary endpoint in Part 1 and Part 2 expansion.",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "OTX-2002",
                        "arm_internal_id": 0,
                        "arm_description": "Monotherapy: OTX-2002 (Cycle length = 4 weeks) OTX-2002 will be administered as an IV infusion over 80-120 minutes every 2 weeks",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: OTX-2002",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "OTX-2002 + Tyrosine Kinase Inhibitor One",
                        "arm_internal_id": 1,
                        "arm_description": "OTX-2002 + Tyrosine Kinase Inhibitor One: (Cycle length = 4 weeks) OTX-2002 will be administered as an IV infusion over 80-120 minutes every 2 weeks.\n\nTyrosine Kinase Inhibitor One will be standard per the respective fixed local approved dose",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: OTX-2002",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Tyrosine kinase inhibitor One",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "OTX-2002 + Tyrosine Kinase Inhibitor Two",
                        "arm_internal_id": 2,
                        "arm_description": "OTX-2002 + Tyrosine Kinase Inhibitor Two : (Cycle length = 4 weeks) OTX-2002 will be administered as an IV infusion over 80-120 minutes every 2 weeks.\n\nTyrosine Kinase Inhibitor Two will be standard per the respective fixed local approved dose",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: OTX-2002",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Tyrosine kinase inhibitor Two",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "OTX-2002 + Checkpoint Inhibitor",
                        "arm_internal_id": 3,
                        "arm_description": "OTX-2002 + Immune Checkpoint Blockade: (Cycle length = 6 weeks) OTX-2002 will be administered as an IV infusion over 80-120 minutes every 2 weeks.\n\nCheckpoint Inhibitor will be standard per the respective fixed local approved dose",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: OTX-2002",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Checkpoint Inhibitor, Immune",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "or": [
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Malignant Rhabdoid Tumor of the Liver"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Liver Angiosarcoma"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Hepatocellular Carcinoma plus Intrahepatic Cholangiocarcinoma"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Malignant Nonepithelial Tumor of the Liver"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Undifferentiated Embryonal Sarcoma of the Liver"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Hepatocellular Carcinoma"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Hepatoblastoma"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Fibrolamellar Carcinoma"
                                        }
                                    }
                                ]
                            },
                            {
                                "clinical": {
                                    "age_numerical": ">=18",
                                    "disease_status": [
                                        "Metastatic",
                                        "Advanced",
                                        "Recurrent",
                                        "Refractory",
                                        "Untreated"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        ]
    }
}